Abstract
SUMMARY: In current practice, gadolinium-based contrast agents have been considered safe when used at clinically recommended doses in patients without severe renal insufficiency. The causal relationship between gadolinium-based contrast agents and nephrogenic systemic fibrosis in patients with renal insufficiency resulted in new policies regarding the administration of these agents. After an effective screening of patients with renal disease by performing either unenhanced or reduced-dose-enhanced studies in these patients and by using the most stable contrast agents, nephrogenic systemic fibrosis has been largely eliminated since 2009. Evidence of in vivo gadolinium deposition in bone tissue in patients with normal renal function is well-established, but recent literature showing that gadolinium might also deposit in the brain in patients with intact blood-brain barriers caught many individuals in the imaging community by surprise. The purpose of this review was to summarize the literature on gadolinium-based contrast agents, tying together information on agent stability and animal and human studies, and to emphasize that low-stability agents are the ones most often associated with brain deposition.
Abbreviations
- DN
- dentate nuclei
- GBCA
- gadolinium-based contrast agent
- NSF
- nephrogenic systemic fibrosis
- © 2016 American Society of Neuroradiology
Indicates open access to non-subscribers at www.ajnr.org
Jump to section
Related Articles
Cited By...
- Is Contrast Medium Really Needed for Follow-up MRI of Untreated Intracranial Meningiomas?
- Conjugates of neuroprotective chaperone L-PGDS provide MRI contrast for detection of amyloid {beta}-rich regions in live Alzheimers Disease mouse model brain
- Safety of Gadolinium-Based Contrast Agents in Patients with Stage 4 and 5 Chronic Kidney Disease: a Radiologists Perspective
- Signal Hyperintensity on Unenhanced T1-Weighted Brain and Cervical Spinal Cord MR Images after Multiple Doses of Linear Gadolinium-Based Contrast Agent
- Fatal gadolinium-induced encephalopathy following accidental intrathecal administration: a case report and a comprehensive evidence-based review
- Brain Tumor-Enhancement Visualization and Morphometric Assessment: A Comparison of MPRAGE, SPACE, and VIBE MRI Techniques
- Gadolinium Deposition in Deep Brain Structures: Relationship with Dose and Ionization of Linear Gadolinium-Based Contrast Agents
- What Have We Learned from Perfusion MRI in Multiple Sclerosis?
- Placental physiology monitored by hyperpolarized dynamic 13C magnetic resonance
- Skin changes after a magnetic resonance imaging scan
- Redefining the Pulvinar Sign in Fabry Disease
- Cumulative Dose of Macrocyclic Gadolinium-Based Contrast Agent Improves Detection of Enhancing Lesions in Patients with Multiple Sclerosis
- Appropriate Minimal Dose of Gadobutrol for 3D Time-Resolved MRA of the Supra-Aortic Arteries: Comparison with Conventional Single-Phase High-Resolution 3D Contrast-Enhanced MRA
- GBCAs and Risk for Nephrogenic Systemic Fibrosis: A Literature Review
- Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity
- Evaluation of Encephaloduroarteriosynangiosis Efficacy Using Probabilistic Independent Component Analysis Applied to Dynamic Susceptibility Contrast Perfusion MRI
- Do Gadolinium-Based Contrast Agents Affect 18F-FDG PET/CT Uptake in the Dentate Nucleus and the Globus Pallidus? A Pilot Study
- Intracranial Arteriovenous Shunting: Detection with Arterial Spin-Labeling and Susceptibility-Weighted Imaging Combined
- Addressing Concerns Regarding the Use of Gadolinium in a Standardized MRI Protocol for the Diagnosis and Follow-Up of Multiple Sclerosis
- Reply:
- Macrocyclic Gadolinium-Based Contrast Agents Do Not Cause Hyperintensity in the Dentate Nucleus